nodes	percent_of_prediction	percent_of_DWPC	metapath
Triamterene—Acute interstitial nephritis—Sorafenib—liver cancer	0.0838	0.361	CcSEcCtD
Triamterene—SCNN1A—Stimuli-sensing channels—SLC9C1—liver cancer	0.048	0.0625	CbGpPWpGaD
Triamterene—SCNN1B—Stimuli-sensing channels—SLC9C1—liver cancer	0.048	0.0625	CbGpPWpGaD
Triamterene—SCNN1D—Stimuli-sensing channels—SLC9C1—liver cancer	0.048	0.0625	CbGpPWpGaD
Triamterene—SCNN1G—Stimuli-sensing channels—SLC9C1—liver cancer	0.048	0.0625	CbGpPWpGaD
Triamterene—SCNN1G—Ion channel transport—SLC9C1—liver cancer	0.0313	0.0408	CbGpPWpGaD
Triamterene—SCNN1A—Ion channel transport—SLC9C1—liver cancer	0.0313	0.0408	CbGpPWpGaD
Triamterene—SCNN1D—Ion channel transport—SLC9C1—liver cancer	0.0313	0.0408	CbGpPWpGaD
Triamterene—SCNN1B—Ion channel transport—SLC9C1—liver cancer	0.0313	0.0408	CbGpPWpGaD
Triamterene—Tubulointerstitial nephritis—Sorafenib—liver cancer	0.0148	0.0639	CcSEcCtD
Triamterene—SCNN1G—Ion channel transport—ATP7B—liver cancer	0.0147	0.0191	CbGpPWpGaD
Triamterene—SCNN1A—Ion channel transport—ATP7B—liver cancer	0.0147	0.0191	CbGpPWpGaD
Triamterene—SCNN1D—Ion channel transport—ATP7B—liver cancer	0.0147	0.0191	CbGpPWpGaD
Triamterene—SCNN1B—Ion channel transport—ATP7B—liver cancer	0.0147	0.0191	CbGpPWpGaD
Triamterene—SCNN1G—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.0109	0.0142	CbGpPWpGaD
Triamterene—SCNN1A—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.0109	0.0142	CbGpPWpGaD
Triamterene—SCNN1D—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.0109	0.0142	CbGpPWpGaD
Triamterene—SCNN1G—Transmembrane transport of small molecules—MYO5B—liver cancer	0.0109	0.0142	CbGpPWpGaD
Triamterene—SCNN1A—Transmembrane transport of small molecules—MYO5B—liver cancer	0.0109	0.0142	CbGpPWpGaD
Triamterene—SCNN1B—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.0109	0.0142	CbGpPWpGaD
Triamterene—SCNN1D—Transmembrane transport of small molecules—MYO5B—liver cancer	0.0109	0.0142	CbGpPWpGaD
Triamterene—SCNN1B—Transmembrane transport of small molecules—MYO5B—liver cancer	0.0109	0.0142	CbGpPWpGaD
Triamterene—CYP1A2—Arylamine metabolism—NAT2—liver cancer	0.0101	0.0131	CbGpPWpGaD
Triamterene—Renal failure acute—Sorafenib—liver cancer	0.00892	0.0385	CcSEcCtD
Triamterene—Hypokalaemia—Sorafenib—liver cancer	0.0075	0.0323	CcSEcCtD
Triamterene—Jaundice—Sorafenib—liver cancer	0.00619	0.0267	CcSEcCtD
Triamterene—SCNN1D—Transmembrane transport of small molecules—SLC11A2—liver cancer	0.00558	0.00726	CbGpPWpGaD
Triamterene—SCNN1B—Transmembrane transport of small molecules—SLC11A2—liver cancer	0.00558	0.00726	CbGpPWpGaD
Triamterene—SCNN1A—Transmembrane transport of small molecules—SLC11A2—liver cancer	0.00558	0.00726	CbGpPWpGaD
Triamterene—SCNN1G—Transmembrane transport of small molecules—SLC11A2—liver cancer	0.00558	0.00726	CbGpPWpGaD
Triamterene—SCNN1D—Transmembrane transport of small molecules—SLC40A1—liver cancer	0.00532	0.00693	CbGpPWpGaD
Triamterene—SCNN1B—Transmembrane transport of small molecules—SLC40A1—liver cancer	0.00532	0.00693	CbGpPWpGaD
Triamterene—SCNN1G—Transmembrane transport of small molecules—SLC40A1—liver cancer	0.00532	0.00693	CbGpPWpGaD
Triamterene—SCNN1A—Transmembrane transport of small molecules—SLC40A1—liver cancer	0.00532	0.00693	CbGpPWpGaD
Triamterene—SCNN1D—Stimuli-sensing channels—RAF1—liver cancer	0.00511	0.00665	CbGpPWpGaD
Triamterene—SCNN1A—Stimuli-sensing channels—RAF1—liver cancer	0.00511	0.00665	CbGpPWpGaD
Triamterene—SCNN1G—Stimuli-sensing channels—RAF1—liver cancer	0.00511	0.00665	CbGpPWpGaD
Triamterene—SCNN1B—Stimuli-sensing channels—RAF1—liver cancer	0.00511	0.00665	CbGpPWpGaD
Triamterene—SCNN1D—Transmembrane transport of small molecules—ATP7B—liver cancer	0.0051	0.00664	CbGpPWpGaD
Triamterene—SCNN1B—Transmembrane transport of small molecules—ATP7B—liver cancer	0.0051	0.00664	CbGpPWpGaD
Triamterene—SCNN1A—Transmembrane transport of small molecules—ANXA2—liver cancer	0.0051	0.00664	CbGpPWpGaD
Triamterene—SCNN1G—Transmembrane transport of small molecules—ANXA2—liver cancer	0.0051	0.00664	CbGpPWpGaD
Triamterene—SCNN1B—Transmembrane transport of small molecules—ANXA2—liver cancer	0.0051	0.00664	CbGpPWpGaD
Triamterene—SCNN1D—Transmembrane transport of small molecules—ANXA2—liver cancer	0.0051	0.00664	CbGpPWpGaD
Triamterene—SCNN1G—Transmembrane transport of small molecules—ATP7B—liver cancer	0.0051	0.00664	CbGpPWpGaD
Triamterene—SCNN1A—Transmembrane transport of small molecules—ATP7B—liver cancer	0.0051	0.00664	CbGpPWpGaD
Triamterene—SCNN1D—Transmembrane transport of small molecules—NR1H4—liver cancer	0.00482	0.00628	CbGpPWpGaD
Triamterene—SCNN1B—Transmembrane transport of small molecules—NR1H4—liver cancer	0.00482	0.00628	CbGpPWpGaD
Triamterene—SCNN1G—Transmembrane transport of small molecules—NR1H4—liver cancer	0.00482	0.00628	CbGpPWpGaD
Triamterene—SCNN1A—Transmembrane transport of small molecules—NR1H4—liver cancer	0.00482	0.00628	CbGpPWpGaD
Triamterene—CYP1A2—Aflatoxin B1 metabolism—GSTM1—liver cancer	0.0044	0.00572	CbGpPWpGaD
Triamterene—CYP1A2—Estrogen metabolism—GSTA1—liver cancer	0.00423	0.00551	CbGpPWpGaD
Triamterene—Dry mouth—Sorafenib—liver cancer	0.00413	0.0178	CcSEcCtD
Triamterene—Hyperkalaemia—Epirubicin—liver cancer	0.00412	0.0178	CcSEcCtD
Triamterene—Anaphylactic shock—Sorafenib—liver cancer	0.00405	0.0175	CcSEcCtD
Triamterene—Thrombocytopenia—Sorafenib—liver cancer	0.00396	0.0171	CcSEcCtD
Triamterene—Blood urea increased—Epirubicin—liver cancer	0.00396	0.0171	CcSEcCtD
Triamterene—Hyperkalaemia—Doxorubicin—liver cancer	0.00381	0.0164	CcSEcCtD
Triamterene—CYP1A2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—liver cancer	0.00375	0.00488	CbGpPWpGaD
Triamterene—Blood urea increased—Doxorubicin—liver cancer	0.00366	0.0158	CcSEcCtD
Triamterene—Fatigue—Sorafenib—liver cancer	0.00349	0.015	CcSEcCtD
Triamterene—Photosensitivity—Epirubicin—liver cancer	0.00347	0.0149	CcSEcCtD
Triamterene—CYP1A2—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—liver cancer	0.00341	0.00444	CbGpPWpGaD
Triamterene—SCNN1A—Ion channel transport—RAF1—liver cancer	0.00333	0.00434	CbGpPWpGaD
Triamterene—SCNN1D—Ion channel transport—RAF1—liver cancer	0.00333	0.00434	CbGpPWpGaD
Triamterene—SCNN1B—Ion channel transport—RAF1—liver cancer	0.00333	0.00434	CbGpPWpGaD
Triamterene—SCNN1G—Ion channel transport—RAF1—liver cancer	0.00333	0.00434	CbGpPWpGaD
Triamterene—Renal failure acute—Epirubicin—liver cancer	0.0033	0.0142	CcSEcCtD
Triamterene—Photosensitivity—Doxorubicin—liver cancer	0.00321	0.0138	CcSEcCtD
Triamterene—Renal failure acute—Doxorubicin—liver cancer	0.00305	0.0132	CcSEcCtD
Triamterene—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1H4—liver cancer	0.00301	0.00392	CbGpPWpGaD
Triamterene—CYP1A2—Fatty Acid Omega Oxidation—CYP2E1—liver cancer	0.00299	0.0039	CbGpPWpGaD
Triamterene—Hypersensitivity—Sorafenib—liver cancer	0.00298	0.0129	CcSEcCtD
Triamterene—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I3—liver cancer	0.00296	0.00385	CbGpPWpGaD
Triamterene—Asthenia—Sorafenib—liver cancer	0.0029	0.0125	CcSEcCtD
Triamterene—Hypokalaemia—Epirubicin—liver cancer	0.00277	0.0119	CcSEcCtD
Triamterene—Diarrhoea—Sorafenib—liver cancer	0.00277	0.0119	CcSEcCtD
Triamterene—Dizziness—Sorafenib—liver cancer	0.00268	0.0115	CcSEcCtD
Triamterene—Vomiting—Sorafenib—liver cancer	0.00257	0.0111	CcSEcCtD
Triamterene—Hypokalaemia—Doxorubicin—liver cancer	0.00256	0.0111	CcSEcCtD
Triamterene—Rash—Sorafenib—liver cancer	0.00255	0.011	CcSEcCtD
Triamterene—Dermatitis—Sorafenib—liver cancer	0.00255	0.011	CcSEcCtD
Triamterene—CYP1A2—Estrogen Receptor Pathway—CYP1A1—liver cancer	0.00254	0.00331	CbGpPWpGaD
Triamterene—Headache—Sorafenib—liver cancer	0.00254	0.0109	CcSEcCtD
Triamterene—CYP1A2—Xenobiotics—CYP2E1—liver cancer	0.0025	0.00326	CbGpPWpGaD
Triamterene—SCNN1D—Transmembrane transport of small molecules—CYCS—liver cancer	0.00246	0.0032	CbGpPWpGaD
Triamterene—SCNN1A—Transmembrane transport of small molecules—CYCS—liver cancer	0.00246	0.0032	CbGpPWpGaD
Triamterene—SCNN1G—Transmembrane transport of small molecules—CYCS—liver cancer	0.00246	0.0032	CbGpPWpGaD
Triamterene—SCNN1B—Transmembrane transport of small molecules—CYCS—liver cancer	0.00246	0.0032	CbGpPWpGaD
Triamterene—CYP1A2—Tamoxifen metabolism—CYP2E1—liver cancer	0.00241	0.00314	CbGpPWpGaD
Triamterene—CYP1A2—Phase II conjugation—UGDH—liver cancer	0.00241	0.00313	CbGpPWpGaD
Triamterene—Nausea—Sorafenib—liver cancer	0.0024	0.0104	CcSEcCtD
Triamterene—Photosensitivity reaction—Epirubicin—liver cancer	0.0024	0.0104	CcSEcCtD
Triamterene—CYP1A2—Aflatoxin activation and detoxification—GGT1—liver cancer	0.0024	0.00312	CbGpPWpGaD
Triamterene—CYP1A2—Estrogen Receptor Pathway—PPARA—liver cancer	0.00232	0.00302	CbGpPWpGaD
Triamterene—Jaundice—Epirubicin—liver cancer	0.00229	0.00986	CcSEcCtD
Triamterene—Photosensitivity reaction—Doxorubicin—liver cancer	0.00222	0.00958	CcSEcCtD
Triamterene—CYP1A2—Fatty Acid Omega Oxidation—CYP1A1—liver cancer	0.00215	0.0028	CbGpPWpGaD
Triamterene—SCNN1G—Transmembrane transport of small molecules—HMOX1—liver cancer	0.00214	0.00278	CbGpPWpGaD
Triamterene—SCNN1A—Transmembrane transport of small molecules—HMOX1—liver cancer	0.00214	0.00278	CbGpPWpGaD
Triamterene—SCNN1B—Transmembrane transport of small molecules—HMOX1—liver cancer	0.00214	0.00278	CbGpPWpGaD
Triamterene—SCNN1D—Transmembrane transport of small molecules—HMOX1—liver cancer	0.00214	0.00278	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12A—liver cancer	0.00212	0.00276	CbGpPWpGaD
Triamterene—Jaundice—Doxorubicin—liver cancer	0.00212	0.00912	CcSEcCtD
Triamterene—CYP1A2—Estrogen Receptor Pathway—ESR1—liver cancer	0.0021	0.00274	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—GSTA2—liver cancer	0.00207	0.00269	CbGpPWpGaD
Triamterene—CYP1A2—Estrogen metabolism—GSTM1—liver cancer	0.00207	0.00269	CbGpPWpGaD
Triamterene—CYP1A2—Estrogen metabolism—CYP1A1—liver cancer	0.00196	0.00255	CbGpPWpGaD
Triamterene—CYP1A2—Cytochrome P450 - arranged by substrate type—NR1H4—liver cancer	0.00191	0.00249	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—AHR—liver cancer	0.00181	0.00235	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—AHR—liver cancer	0.00181	0.00235	CbGpPWpGaD
Triamterene—CYP1A2—Xenobiotics—CYP1A1—liver cancer	0.0018	0.00234	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—NFE2L2—liver cancer	0.00176	0.00229	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—NFE2L2—liver cancer	0.00176	0.00229	CbGpPWpGaD
Triamterene—CYP1A2—Tamoxifen metabolism—CYP1A1—liver cancer	0.00173	0.00225	CbGpPWpGaD
Triamterene—SCNN1G—Transmembrane transport of small molecules—PPARA—liver cancer	0.00173	0.00225	CbGpPWpGaD
Triamterene—SCNN1A—Transmembrane transport of small molecules—PPARA—liver cancer	0.00173	0.00225	CbGpPWpGaD
Triamterene—SCNN1B—Transmembrane transport of small molecules—PPARA—liver cancer	0.00173	0.00225	CbGpPWpGaD
Triamterene—SCNN1D—Transmembrane transport of small molecules—PPARA—liver cancer	0.00173	0.00225	CbGpPWpGaD
Triamterene—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—liver cancer	0.00164	0.00213	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—liver cancer	0.00158	0.00205	CbGpPWpGaD
Triamterene—CYP1A2—Phase 1 - Functionalization of compounds—NR1H4—liver cancer	0.00155	0.00202	CbGpPWpGaD
Triamterene—Dry mouth—Epirubicin—liver cancer	0.00153	0.00658	CcSEcCtD
Triamterene—Anaphylactic shock—Epirubicin—liver cancer	0.0015	0.00645	CcSEcCtD
Triamterene—CYP1A2—Arachidonic acid metabolism—HPGDS—liver cancer	0.00148	0.00192	CbGpPWpGaD
Triamterene—Thrombocytopenia—Epirubicin—liver cancer	0.00146	0.00632	CcSEcCtD
Triamterene—Dry mouth—Doxorubicin—liver cancer	0.00141	0.00609	CcSEcCtD
Triamterene—CYP1A2—Biological oxidations—UGDH—liver cancer	0.00141	0.00183	CbGpPWpGaD
Triamterene—Anaphylactic shock—Doxorubicin—liver cancer	0.00138	0.00597	CcSEcCtD
Triamterene—CYP1A2—Phase II conjugation—GSTA3—liver cancer	0.00138	0.0018	CbGpPWpGaD
Triamterene—CYP1A2—Estrogen Receptor Pathway—JUN—liver cancer	0.00136	0.00177	CbGpPWpGaD
Triamterene—Thrombocytopenia—Doxorubicin—liver cancer	0.00136	0.00584	CcSEcCtD
Triamterene—CYP1A2—Melatonin metabolism and effects—CYP1A1—liver cancer	0.00134	0.00174	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—liver cancer	0.00133	0.00174	CbGpPWpGaD
Triamterene—Fatigue—Epirubicin—liver cancer	0.00129	0.00556	CcSEcCtD
Triamterene—CYP1A2—Tryptophan metabolism—CYP2E1—liver cancer	0.00129	0.00167	CbGpPWpGaD
Triamterene—SCNN1B—Transmembrane transport of small molecules—ALB—liver cancer	0.00128	0.00167	CbGpPWpGaD
Triamterene—SCNN1G—Transmembrane transport of small molecules—ALB—liver cancer	0.00128	0.00167	CbGpPWpGaD
Triamterene—SCNN1D—Transmembrane transport of small molecules—ALB—liver cancer	0.00128	0.00167	CbGpPWpGaD
Triamterene—SCNN1A—Transmembrane transport of small molecules—ALB—liver cancer	0.00128	0.00167	CbGpPWpGaD
Triamterene—CYP1A2—Phase II conjugation—GSTA4—liver cancer	0.00126	0.00165	CbGpPWpGaD
Triamterene—CYP1A2—Phase II conjugation—GSTA2—liver cancer	0.00123	0.0016	CbGpPWpGaD
Triamterene—Fatigue—Doxorubicin—liver cancer	0.00119	0.00515	CcSEcCtD
Triamterene—CYP1A2—Phase II conjugation—GSTA1—liver cancer	0.00119	0.00155	CbGpPWpGaD
Triamterene—CYP1A2—Estrogen Receptor Pathway—STAT3—liver cancer	0.00118	0.00153	CbGpPWpGaD
Triamterene—CYP1A2—Phase II conjugation—NAT2—liver cancer	0.00117	0.00153	CbGpPWpGaD
Triamterene—SCNN1G—Transmembrane transport of small molecules—RAF1—liver cancer	0.00116	0.00151	CbGpPWpGaD
Triamterene—SCNN1D—Transmembrane transport of small molecules—RAF1—liver cancer	0.00116	0.00151	CbGpPWpGaD
Triamterene—SCNN1A—Transmembrane transport of small molecules—RAF1—liver cancer	0.00116	0.00151	CbGpPWpGaD
Triamterene—SCNN1B—Transmembrane transport of small molecules—RAF1—liver cancer	0.00116	0.00151	CbGpPWpGaD
Triamterene—CYP1A2—Arachidonic acid metabolism—GGT1—liver cancer	0.0011	0.00144	CbGpPWpGaD
Triamterene—Hypersensitivity—Epirubicin—liver cancer	0.0011	0.00475	CcSEcCtD
Triamterene—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—liver cancer	0.00108	0.0014	CbGpPWpGaD
Triamterene—Asthenia—Epirubicin—liver cancer	0.00107	0.00463	CcSEcCtD
Triamterene—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2E1—liver cancer	0.00104	0.00135	CbGpPWpGaD
Triamterene—CYP1A2—Oxidation by Cytochrome P450—CYP2E1—liver cancer	0.00103	0.00134	CbGpPWpGaD
Triamterene—Diarrhoea—Epirubicin—liver cancer	0.00102	0.00441	CcSEcCtD
Triamterene—Hypersensitivity—Doxorubicin—liver cancer	0.00102	0.0044	CcSEcCtD
Triamterene—Asthenia—Doxorubicin—liver cancer	0.000993	0.00428	CcSEcCtD
Triamterene—Dizziness—Epirubicin—liver cancer	0.000989	0.00427	CcSEcCtD
Triamterene—Vomiting—Epirubicin—liver cancer	0.000951	0.0041	CcSEcCtD
Triamterene—Diarrhoea—Doxorubicin—liver cancer	0.000947	0.00408	CcSEcCtD
Triamterene—Rash—Epirubicin—liver cancer	0.000943	0.00407	CcSEcCtD
Triamterene—Dermatitis—Epirubicin—liver cancer	0.000942	0.00406	CcSEcCtD
Triamterene—CYP1A2—Phase II conjugation—HPGDS—liver cancer	0.000939	0.00122	CbGpPWpGaD
Triamterene—Headache—Epirubicin—liver cancer	0.000937	0.00404	CcSEcCtD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—liver cancer	0.000924	0.0012	CbGpPWpGaD
Triamterene—CYP1A2—Tryptophan metabolism—CYP1A1—liver cancer	0.000924	0.0012	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—liver cancer	0.000924	0.0012	CbGpPWpGaD
Triamterene—Dizziness—Doxorubicin—liver cancer	0.000915	0.00395	CcSEcCtD
Triamterene—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	0.00089	0.00116	CbGpPWpGaD
Triamterene—Nausea—Epirubicin—liver cancer	0.000889	0.00383	CcSEcCtD
Triamterene—Vomiting—Doxorubicin—liver cancer	0.00088	0.00379	CcSEcCtD
Triamterene—Rash—Doxorubicin—liver cancer	0.000873	0.00376	CcSEcCtD
Triamterene—Dermatitis—Doxorubicin—liver cancer	0.000872	0.00376	CcSEcCtD
Triamterene—Headache—Doxorubicin—liver cancer	0.000867	0.00374	CcSEcCtD
Triamterene—CYP1A2—Arachidonic acid metabolism—CYP1A1—liver cancer	0.000865	0.00113	CbGpPWpGaD
Triamterene—CYP1A2—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	0.000843	0.0011	CbGpPWpGaD
Triamterene—Nausea—Doxorubicin—liver cancer	0.000822	0.00355	CcSEcCtD
Triamterene—CYP1A2—Biological oxidations—NR1H4—liver cancer	0.000822	0.00107	CbGpPWpGaD
Triamterene—CYP1A2—Biological oxidations—GSTA3—liver cancer	0.000808	0.00105	CbGpPWpGaD
Triamterene—CYP1A2—Metapathway biotransformation—GSTA3—liver cancer	0.000797	0.00104	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—liver cancer	0.000766	0.000997	CbGpPWpGaD
Triamterene—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—liver cancer	0.000747	0.000973	CbGpPWpGaD
Triamterene—CYP1A2—Biological oxidations—GSTA4—liver cancer	0.000739	0.000962	CbGpPWpGaD
Triamterene—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—liver cancer	0.000737	0.00096	CbGpPWpGaD
Triamterene—CYP1A2—Metapathway biotransformation—GSTA4—liver cancer	0.000729	0.000949	CbGpPWpGaD
Triamterene—CYP1A2—Biological oxidations—GSTA2—liver cancer	0.00072	0.000938	CbGpPWpGaD
Triamterene—CYP1A2—Phase II conjugation—GGT1—liver cancer	0.000703	0.000915	CbGpPWpGaD
Triamterene—CYP1A2—Biological oxidations—GSTA1—liver cancer	0.000695	0.000905	CbGpPWpGaD
Triamterene—CYP1A2—Biological oxidations—NAT2—liver cancer	0.000687	0.000895	CbGpPWpGaD
Triamterene—CYP1A2—Metapathway biotransformation—NAT2—liver cancer	0.000678	0.000882	CbGpPWpGaD
Triamterene—CYP1A2—Phase II conjugation—GSTP1—liver cancer	0.000631	0.000822	CbGpPWpGaD
Triamterene—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	0.000606	0.000789	CbGpPWpGaD
Triamterene—CYP1A2—Phase II conjugation—GSTM1—liver cancer	0.00058	0.000755	CbGpPWpGaD
Triamterene—CYP1A2—Metapathway biotransformation—GPX3—liver cancer	0.000576	0.00075	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—liver cancer	0.000568	0.00074	CbGpPWpGaD
Triamterene—CYP1A2—Biological oxidations—HPGDS—liver cancer	0.000549	0.000715	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—liver cancer	0.000521	0.000678	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—liver cancer	0.000521	0.000678	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—liver cancer	0.000509	0.000663	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—EPT1—liver cancer	0.000508	0.000662	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—liver cancer	0.000496	0.000645	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—liver cancer	0.00048	0.000625	CbGpPWpGaD
Triamterene—CYP1A2—Biological oxidations—CYP2E1—liver cancer	0.000448	0.000583	CbGpPWpGaD
Triamterene—CYP1A2—Metapathway biotransformation—CYP2E1—liver cancer	0.000442	0.000575	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—liver cancer	0.000433	0.000564	CbGpPWpGaD
Triamterene—CYP1A2—Biological oxidations—GGT1—liver cancer	0.000411	0.000535	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—MYC—liver cancer	0.000398	0.000519	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—liver cancer	0.000397	0.000517	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—liver cancer	0.000371	0.000483	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—TNF—liver cancer	0.000371	0.000483	CbGpPWpGaD
Triamterene—CYP1A2—Biological oxidations—GSTP1—liver cancer	0.000369	0.000481	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—liver cancer	0.000368	0.000479	CbGpPWpGaD
Triamterene—CYP1A2—Metapathway biotransformation—GSTP1—liver cancer	0.000364	0.000474	CbGpPWpGaD
Triamterene—CYP1A2—Biological oxidations—GSTM1—liver cancer	0.000339	0.000442	CbGpPWpGaD
Triamterene—CYP1A2—Metapathway biotransformation—GSTM1—liver cancer	0.000335	0.000436	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	0.000327	0.000426	CbGpPWpGaD
Triamterene—CYP1A2—Biological oxidations—CYP1A1—liver cancer	0.000322	0.000419	CbGpPWpGaD
Triamterene—CYP1A2—Metapathway biotransformation—CYP1A1—liver cancer	0.000317	0.000413	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	0.000316	0.000411	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—liver cancer	0.000313	0.000407	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	0.000241	0.000314	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—UGDH—liver cancer	0.000241	0.000313	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—EPT1—liver cancer	0.000226	0.000295	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—TAT—liver cancer	0.000215	0.000279	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	0.000211	0.000275	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—GGT1—liver cancer	0.000158	0.000206	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—CPT1B—liver cancer	0.000146	0.00019	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—GLUL—liver cancer	0.000146	0.00019	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—NR1H4—liver cancer	0.000141	0.000183	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—GSTA3—liver cancer	0.000138	0.00018	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—GSTA4—liver cancer	0.000126	0.000165	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	0.000124	0.000161	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—GSTA2—liver cancer	0.000123	0.00016	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—GSTA1—liver cancer	0.000119	0.000155	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—NAT2—liver cancer	0.000118	0.000153	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—liver cancer	0.000113	0.000147	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—ALDOB—liver cancer	0.000113	0.000147	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—CRABP1—liver cancer	0.000107	0.00014	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	9.68e-05	0.000126	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—HPGDS—liver cancer	9.4e-05	0.000122	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	9.34e-05	0.000122	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	8.51e-05	0.000111	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—ALB—liver cancer	8.4e-05	0.000109	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—PSMD10—liver cancer	8.37e-05	0.000109	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—PSMA4—liver cancer	8.37e-05	0.000109	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—GOT2—liver cancer	8.15e-05	0.000106	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—CYP2E1—liver cancer	7.66e-05	9.97e-05	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	7.42e-05	9.66e-05	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—CYCS—liver cancer	7.17e-05	9.33e-05	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—GOT1—liver cancer	7.03e-05	9.16e-05	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—GGT1—liver cancer	7.03e-05	9.16e-05	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—GSTP1—liver cancer	6.32e-05	8.22e-05	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—HMOX1—liver cancer	6.23e-05	8.11e-05	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—GSTM1—liver cancer	5.8e-05	7.56e-05	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—CYP1A1—liver cancer	5.5e-05	7.16e-05	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—MTHFR—liver cancer	5.13e-05	6.68e-05	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—PPARA—liver cancer	5.03e-05	6.55e-05	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	4.52e-05	5.89e-05	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—PIK3CG—liver cancer	4.31e-05	5.61e-05	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—PPARG—liver cancer	4.16e-05	5.42e-05	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—PIK3CD—liver cancer	3.79e-05	4.93e-05	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—ALB—liver cancer	3.74e-05	4.87e-05	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—PIK3CB—liver cancer	3.3e-05	4.3e-05	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—PIK3CA—liver cancer	2.01e-05	2.62e-05	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—AKT1—liver cancer	1.64e-05	2.14e-05	CbGpPWpGaD
